FORT LAUDERDALE, Fla., Oct. 13, 2015 /PRNewswire/ -- Vigilant Biosciences, Inc. ("Vigilant"), a leading innovator and developer of solutions that aid in the early detection and intervention of cancer, announced today that BioFlorida has awarded Vigilant's founder and CEO, Matthew H.J. Kim, the Weaver H. Gaines Entrepreneur of the Year Award, which recognizes an entrepreneur who has made extraordinary contributions to the growth of Florida's life sciences industry in the leadership of a company or institution.
BioFlorida is the voice of Florida's life sciences industry, representing nearly 5,500 establishments and research organizations in the biotechnology, pharmaceuticals, medical devices and bioagriculture sectors that collectively employ nearly 80,000 Floridians. The Weaver H. Gaines Entrepreneur of the Year Award is named in honor of Weaver Gaines, one of the founding directors of BioFlorida.
"We are pleased to present Matthew Kim, CEO of Vigilant Biosciences with this award for his contributions to the Florida life sciences industry and his ongoing passion and commitment to making a meaningful impact in the lives of those at risk for cancer or living with the disease," said Nancy K. Bryan, President and CEO of BioFlorida.
The Weaver H. Gaines Entrepreneur of the Year Award was presented today by Weaver H. Gaines, at the BioFlorida Conference 2015, in Orlando, Fla.
"I am truly honored to be recognized by BioFlorida and to be among the outstanding individuals who have received this award," said Matthew H.J. Kim, Founder, Chairman and CEO of Vigilant Biosciences, Inc. "This accolade is the result of the collaborative effort of the Vigilant Biosciences team, our investors and partners, united in a mission to find a better solution for those impacted by oral cancer. I'd also like to thank the BioFlorida board of directors and commend them for the significant contribution that they have made to the growth and success of the biotechnology industry across the state."
About Vigilant Biosciences, Inc.
Vigilant Biosciences is a leading innovator and developer of solutions that aid clinicians in the early detection and intervention of cancer. Its point-of-care and lab-based products are simple, accurate and cost-effective, empowering healthcare practitioners to easily assess the risk of oral cancer early, and improve outcomes through earlier intervention. The Vigilant Biosciences™ OncAlert™ point-of-care and lab assay products are currently undergoing the CE Mark registration approval process and not yet available for sale in any market at this time. For more information, visit www.vigilantbiosciences.com.
SOURCE Vigilant Biosciences, Inc.